Evolution of the Average Target: MacroGenics, Inc.

Evolution of the Average Target - MacroGenics, Inc.

Evolution of the Target Price: MacroGenics, Inc.

Evolution of the Target Price - MacroGenics, Inc.

Changes in Analyst Recommendations: MacroGenics, Inc.

7a139bbca1cb.61mnkAnoBP_cYBsRkJstxgYqCiPoyMxhO6Qd9arXGJ0.vyrm50u9UZnrOmlgqPhiiysbQWiRo_oqVZNyuMiwafeGGP74faNhtO4aKw~3a70b636b67760d20a63bf07d8ef405b
08-17 B. Riley Raises Price Target on MacroGenics to $11 From $9, Keeps Buy Rating MT
04-10 B. Riley Upgrades MacroGenics to Buy From Neutral, Triples Price Target to $9 From $3 MT
15/08/25 MacroGenics Q2 revenue rises RE
20/05/25 B. Riley Cuts Price Target on MacroGenics to $3 From $5, Keeps Neutral Rating MT
07/11/24 JMP Securities Downgrades MacroGenics to Market Perform MT
01/08/24 BTIG Downgrades MacroGenics to Neutral From Buy MT
31/07/24 B. Riley Downgrades MacroGenics to Neutral From Buy, Adjusts Price Target to $5 From $18 MT
31/07/24 Guggenheim Downgrades MacroGenics to Neutral From Buy; Shares Tumble MT
31/07/24 B. Riley Downgrades MacroGenics to Neutral From Buy, Adjusts Price Target to $5 From $18 MT
10/05/24 BMO Downgrades MacroGenics to Market Perform From Outperform, Price Target at $8 MT
10/05/24 Stifel Downgrades MacroGenics to Hold MT
10/05/24 TD Cowen Downgrades MacroGenics to Hold From Buy MT
26/04/24 B. Riley Securities Initiates MacroGenics With Buy Rating, $25 Price Target MT
09/04/24 TD Cowen Upgrades MacroGenics to Buy From Hold MT
11/03/24 HC Wainwright Adjusts Price Target on MacroGenics to $16 From $14, Maintains Neutral Rating MT
11/03/24 JMP Securities Adjusts Price Target on MacroGenics to $22 From $16, Maintains Market Outperform Rating MT
08/03/24 Stifel Adjusts Price Target on MacroGenics to $29 From $17, Keeps Buy Rating MT
08/03/24 BMO Capital Adjusts Price Target on MacroGenics to $24 From $18, Maintains Outperform Rating MT
04/03/24 BTIG Adjusts Price Target on MacroGenics to $24 From $12, Maintains Buy Rating MT
29/02/24 Barclays Raises Price Target on MacroGenics to $23 From $12, Maintains Overweight Rating MT
14/02/24 HC Wainwright Downgrades MacroGenics to Neutral From Buy, Adjusts Price Target to $14 From $12 MT
24/01/24 JMP Securities Adjusts MacroGenics' Price Target to $16 From $10, Maintains Market Outperform Rating MT
20/12/23 Citigroup Upgrades MacroGenics to Buy From Neutral, Raises Price Target to $13 From $7 MT
13/11/23 HC Wainwright Cuts MacroGenics' Price Target to $12 From $14, Keeps Buy Rating MT
07/11/23 Guggenheim Upgrades MacroGenics to Buy From Neutral, Price Target is $12 MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+227.87%
+41.32%
+28.63%
+9.56%
+12.15%
+19.23%
+39%
+42.31%
+6.5%
+35.02%
Average +46.16%
Weighted average by Cap. +26.27%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
2.440USD
Average target price
8.000USD
Spread / Average Target
+227.87%
High Price Target
11.00USD
Spread / Highest target
+350.82%
Low Price Target
4.000USD
Spread / Lowest Target
+63.93%

Analyst Consensus Detail

Analyst consensus - MacroGenics, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - MacroGenics, Inc.
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - MacroGenics, Inc.
  1. Stock Market
  2. Stocks
  3. MGNX Stock
  4. Consensus MacroGenics, Inc.